Beyond Alzheimer's disease, the modular sensor architecture can be adapted for other neurodegenerative diseases—including Parkinson's and frontotemporal dementia—by targeting biomarkers such as α‐synuclein and p‐tau 217. This evidence concerns the gene MAPT and Parkinsonism.